Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03830320 · ClinicalTrials.gov registry record · Phase 1

Positron Emission Tomography (PET) Imaging of Thrombosis

A Phase 1 study of Cancer and COVID-19, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 1
Development phase
165
Enrollment target
1
Study location

NCT03830320: Recruiting Phase 1 study of Cancer and COVID-19, sponsored by Massachusetts General Hospital.

NCT03830320 is a Phase 1 study of Cancer and COVID-19 that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 165 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03830320, a Phase 1 study of Cancer and COVID-19, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 1
Development phase
165 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Primary Outcome

To model pharmacokinetics of \[64Cu\]FBP8 metabolism in healthy volunteers.

Interventions

  • PROCEDURE Electrocardiogram
  • DRUG [64Cu]FBP8
  • DEVICE PET/MR
  • PROCEDURE Blood Collection

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2016-04-01
Est. Completion 2027-01-31
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

What NCT03830320 shows while recruiting

NCT03830320 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).

The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Electrocardiogram is the first listed.

NCT03830320 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03830320 about?

NCT03830320 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Thrombosis". The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasi...

What is the current status of trial NCT03830320?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2016-04-01. Estimated completion is 2027-01-31.

What conditions does trial NCT03830320 study?

This clinical trial studies the following conditions: Cancer, COVID-19, Atrial Fibrillation, Thrombosis.

What interventions are being tested in trial NCT03830320?

The interventions under investigation include: Electrocardiogram (PROCEDURE), [64Cu]FBP8 (DRUG), PET/MR (DEVICE), Blood Collection (PROCEDURE).

Who is sponsoring clinical trial NCT03830320?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03830320 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03830320's enrollment target sits among peer trials

165 256th of 615 higher than 359 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02387255 · 165 participants

    Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms

  • NCT03351348 · 165 participants · Phase 3

    Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control

  • NCT04289571 · 165 participants · Phase 1

    Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

  • NCT04458584 · 165 participants

    Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03830320, the US trial registry maintained by the National Library of Medicine. NCT03830320 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.